Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Site 32, Budapest

Site 34, Budapest

Site 03, San Fernando

Site 33, Kistarcsa

Site 01, Mar del Plata

Site 05, Mexico City

Site 67, Santiago de Compostela

Site 79, Vinnytsia

Site 24, Salisbury

Site 65, Málaga

Site 11, Chihuahua City

Site 10, Durango

Site 18, Memphis

Site 23, Lexington

Site 71, Seville

Site 17, Middleburg Heights

Site 19, Cincinnati

Site 68, Bilbao

Site 08, Cuautitlán Izcalli

Site 75, Kharkiv

Site 06, Monterrey

Site 77, Odesa

Site 27, Wichita

Site 78, Zaporizhzhia

Site 20, Monroe

Site 13, San Luis Potosí City

Site 04, San Luis Potosí City

Site 07, Culiacán

Site 14, Denver

Site 16, Phoenix

Site 25, Glendale

Site 12, Mérida

Site 21, Seattle

Site 22, Spokane

Site 60, Moscow

Site 55, Yaroslavl

Site 59, Yaroslavl

Site 57, Saint Petersburg

Site 62, Smolensk

Site 56, Izhevsk

Site 58, Novosibirsk

Site 54, Tomsk

Site 61, Kemerovo

Site 26, Lebanon

Site 02, Ciudad Autonoma de Buenos Aires

Site 09, Mexico City

Site 45, Krakow

Site 38, Bialystok

Site 47, Bytom

Site 36, Elblag

Site 39, Katowice

Site 40, Katowice

Site 46, Krakow

Site 43, Lodz

Site 48, Nowa Sól

Site 42, Poznan

Site 53, Sochaczew

Site 50, Warsaw

Site 52, Warsaw

Site 51, Wroclaw

Site 66, Barcelona

Site 64, Barcelona

Site 73, Kiev

Site 74, Kyiv

Site 76, Kyiv

Site 72, Kyiv